Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SGMO is expected to report 3Q20 loss of $ 0.24 per share from revenue of $ 26.55 million.
For the full year, analysts anticipate top line of $ 89.47 million, while looking forward to loss of $ 1.12 per share bottom line.
Previous Quarter Performance
Sangamo Therapeutics, Inc. revealed loss for the second quarter of $ 0.26 per share, from the revenue of $ 21.55 million.
Stock Performance
Shares of Sangamo Therapeutics, Inc. traded up $ 0.27 or 2.60 percent on Tuesday, reaching $ 10.65 with volume of 1.08 million shares. Sangamo Therapeutics, Inc. has traded high as $ 10.74 and has cracked $ 10.15 on the downward trend
According to the previous trading day, closing price of $ 10.65, representing a 115.80 % increase from the 52 week low of $ 4.81 and a 21.36 % decrease over the 52 week high of $ 13.20.
The company has a market capital of $ 1.50 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Sangamo Therapeutics, Inc. will be hosting a conference call at 5:00 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sangamo.com
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companys zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
